Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO

AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar squamous cell carcinoma No hepatic toxicities, grade ≥3 treatment-related adverse events, or dose-limiting toxicities were observed at doses up to 10 mg/kg LEXINGTON, Mass. --(BUSINESS WIRE)--Jun. 5, 2023-- Agenus (Nasdaq: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 (CD137 agonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting. AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily pre-treated patients with solid tumors. “AGEN2373 has shown meaningful single agent activity and a favorable safety profile without evidence of liver toxicity in patients with heavily pretreated cold and immunotherapy resistant tumors,” said Dr. Steven O’Day, MD, Chief Medical Officer at Agenus . “AGEN2373 is designed to selectively boost tumor immunity while limiting hepatotoxicity and off-target effects associated with systemic CD137 activation. These encouraging monotherapy results support further clinical trials for AGEN2373 alone and in combination with our novel immunotherapy programs.” Study Design: AGEN2373 was administered intravenously at doses ranging from 0.03 mg/kg to 10 mg/kg in a cohort of 46 patients with advanced solid tumors and a median of 4 prior lines of therapy. Objective responses: Notable responses in the dose escalation study include: Confirmed partial response in a patient with vulvar squamous cell carcinoma who progressed on prior pembrolizumab Confirmed partial response with complete resolution of the pancreatic lesion in a patient with ampullary carcinoma Confirmed 38% reduction in target liver lesions in a castrate-resistant prostate cancer that was non-evaluable by RECIST due to palliative radiation for bone metastases Tolerability: No hepatic toxicities, grade ≥3 treatment-related adverse events, or dose-limiting toxicities were observed, consistent with the molecule’s design. Presently, AGEN2373 is being evaluated in combination with botensilimab (multi-functional anti-CTLA-4) at a dose of 10 mg/kg in patients with PD-(L)1 refractory melanoma. Presentation Details: Abstract Title: A Phase 1 Study of AGEN2373, a Novel CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients with Advanced Solid Tumors (NCT04121676) Abstract Number: 2524 Poster Number : 366 Presenting Author: Dr. Minal Barve , MD, Executive Director and Chief Medical Officer, Mary Crowley Research The poster presentation can be accessed in the publications section of our website at https://agenusbio.com/publications/ . About AGEN2373 AGEN2373 is a novel anti-CD137 agonist designed to stimulate T and NK cells for a durable memory response to cancer. AGEN2373’s selective binding to a unique epitope is designed to prevent serious side effects associated with CD137 activation in the liver, as reported by competitor molecules. About Agenus Agenus is a clinical-stage immuno-oncology company focused on developing therapies that engage the body's immune system in fighting cancer and infections. The Company's mission is to broaden the patient populations benefiting from cancer immunotherapy through combination approaches, leveraging a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the use of AGEN2373, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action (including validation of mechanism of action), potency, durability, and safety profile (including the absence of specific toxicities) of the Company’s therapeutic candidates; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission . Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. View source version on businesswire.com : https://www.businesswire.com/news/home/20230605005557/en/ Agenus Inc. Zack Armen Investor Relations (917) 362-1370 [email protected] Source: Agenus Inc. View All News Contact Us Agenus Inc. [email protected] Quick Links SEC Filings Information Request Form Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Agenus Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Agenus Inc. to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options Investor Alert Options * News Quarterly Reports Annual Reports SEC Filings End of Day Stock Quote Events & Presentations Unsubscribe Email Alert Sign Up Confirmation Request A Meeting With Management > Agenus Inc. 3 Forbes Road Lexington, MA 02421-7305 T: +1 781.674.4400 | F: +1 781.674.4200 © 2023 Agenus Inc. All rights reserved. Privacy policy Terms and conditions of use Overview Pipeline Capabilities Publications Patients Investors Media In the News Podcast Join us Contact us Download item year list Download Description Internal page banner (opens in new window)

The release as fetched from its publisher. agenusbio.com ↗